Press release
Pharmacogenomics Market is Growing at a CAGR of 10.3% by 2028 | F. Hoffmann-la Roche, Abbott, Oxford Nanopore Technologies, Thermo Fisher Scientific, Illumina etc.
Download Sample PDF: https://www.theinsightpartners.com/sample/TIPRE00007564?utm_source=OpenPR&utm_medium=10770
The pharmacogenomics market is projected to reach US$ 14,107.80 million by 2028 from US$ 7,087.81 million in 2021, registering a CAGR of 10.3% during 2021-2028.
Pharmacogenomics Market Overview
The Pharmacogenomics Market Analysis highlights the increasing integration of genomic data into clinical decision-making and drug development processes. The market is expanding due to the rising burden of chronic diseases such as cardiovascular disorders, cancer, diabetes, and neurological conditions, which require more personalized treatment strategies. According to research insights, a significant proportion of the global population suffers from one or more chronic conditions, creating a strong demand for advanced therapeutic solutions.
Moreover, pharmacogenomics enables healthcare providers to predict patient-specific drug responses, thereby reducing trial-and-error prescribing. This capability is particularly valuable in oncology, where targeted therapies based on genetic profiles are becoming standard practice. The oncology segment currently holds a dominant share in the market due to the increasing incidence of cancer and the need for precision-based treatment protocols.
Technological advancements such as polymerase chain reaction (PCR), next-generation sequencing (NGS), microarrays, and mass spectrometry are driving the market forward. Among these, PCR-based technologies account for a significant market share due to their cost-effectiveness and widespread adoption in clinical diagnostics.
Market Drivers and Trends
One of the primary drivers of the pharmacogenomics market is the increasing prevalence of chronic diseases globally. Genetic predisposition plays a crucial role in many chronic conditions, making pharmacogenomics an essential tool for early diagnosis and treatment optimization.
Another significant factor contributing to market growth is the rising investment in genomic research. Governments and private organizations worldwide are funding large-scale genome sequencing projects to enhance healthcare outcomes. These initiatives are accelerating the adoption of pharmacogenomics in clinical practice.
Explore full report- https://www.theinsightpartners.com/reports/pharmacogenomics-market
Furthermore, advancements in sequencing technologies have significantly reduced the cost of genomic analysis, making pharmacogenomics more accessible. The integration of artificial intelligence and big data analytics is also enhancing the interpretation of genomic data, enabling more accurate predictions of drug responses.
The shift toward personalized medicine is a key trend shaping the market. Healthcare providers are increasingly focusing on patient-centric treatment approaches, which rely heavily on pharmacogenomic insights. This trend is expected to drive sustained demand for pharmacogenomics solutions in the coming years.
Market Segmentation Overview
The pharmacogenomics market is segmented based on technology, application, end user, and geography.
By technology, the market includes PCR, sequencing, microarray, gel electrophoresis, and mass spectrometry. PCR remains the dominant segment due to its reliability and efficiency in genetic testing.
By application, the market is categorized into drug discovery, oncology, neurology and psychiatry, pain management, and cardiovascular diseases. Among these, oncology leads the market due to the increasing adoption of targeted cancer therapies.
By end user, the market includes hospitals and clinics, biopharmaceutical companies, and contract research organizations (CROs) and contract development and manufacturing organizations (CDMOs). CROs and CDMOs play a crucial role in supporting clinical trials and drug development processes.
Geographically, North America dominates the pharmacogenomics market due to the presence of advanced healthcare infrastructure, strong research capabilities, and significant investments in precision medicine. Meanwhile, the Asia-Pacific region is expected to witness the fastest growth, driven by increasing healthcare expenditure and growing awareness of personalized medicine.
Top Key Players in the Pharmacogenomics Market
Leading companies in the pharmacogenomics market are focusing on strategic collaborations, product innovations, and technological advancements to strengthen their market position. Key players include:
• Abbott Laboratories
• F. Hoffmann-La Roche Ltd
• Thermo Fisher Scientific Inc.
• QIAGEN N.V.
• Illumina, Inc.
• Myriad Genetics, Inc.
• Agilent Technologies, Inc.
• Oxford Nanopore Technologies
• Admera Health
• Dynamic DNA Laboratories
These companies are actively investing in research and development to expand their product portfolios and enhance their capabilities in genomic analysis and precision medicine.
Purchase a Copy of this report: https://www.theinsightpartners.com/buy/TIPRE00007564?utm_source=OpenPR&utm_medium=10770
Future Outlook
The future of the pharmacogenomics market looks highly promising, driven by continuous advancements in genomic technologies and increasing adoption of personalized healthcare solutions. The integration of artificial intelligence, machine learning, and big data analytics is expected to revolutionize pharmacogenomics by enabling more precise and efficient analysis of complex genetic data.
Additionally, the growing focus on preventive healthcare and early disease detection will further boost the demand for pharmacogenomics solutions. As healthcare systems worldwide shift toward value-based care, pharmacogenomics will play a critical role in improving patient outcomes and reducing healthcare costs.
Emerging markets, particularly in Asia-Pacific, are expected to offer significant growth opportunities due to improving healthcare infrastructure and increasing investments in biotechnology research. The expansion of genomic databases and biobanks will also contribute to the development of more accurate and comprehensive pharmacogenomic tests.
Related Reports:
Oncology Molecular Diagnostics Market - https://www.theinsightpartners.com/reports/oncology-molecular-diagnostics-market
Oncology Companion Diagnostics Market- https://www.theinsightpartners.com/reports/oncology-companion-diagnostics-market
Contact Us
Contact Person: Ankit Mathur
Phone: +1-646-491-9876
Email: sales@theinsightpartners.com
About Us
The Insight Partners is a leading provider of actionable market intelligence and consulting services across various industries. Our research reports combine advanced analytics, expert insights, and reliable data to help organizations identify new opportunities, optimize strategies, and achieve sustainable growth. We specialize in delivering in-depth market studies covering healthcare, technology, manufacturing, and emerging sectors.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Pharmacogenomics Market is Growing at a CAGR of 10.3% by 2028 | F. Hoffmann-la Roche, Abbott, Oxford Nanopore Technologies, Thermo Fisher Scientific, Illumina etc. here
News-ID: 4485271 • Views: …
More Releases from The Insight Parntners
Cell and Gene Therapy Contract Development and Manufacturing Organization Market …
The global Cell and Gene Therapy Contract Development and Manufacturing Organization Market is witnessing rapid expansion as biopharmaceutical companies increasingly outsource complex development and manufacturing processes. Cell and gene therapies represent a transformative approach to treating chronic, genetic, and life-threatening diseases, including cancer and rare disorders. As the demand for these advanced therapies rises, contract development and manufacturing organizations are playing a pivotal role in enabling scalable, compliant, and cost-effective…
Digital PCR and Real-Time PCR Market Leading Players Analysis - QIAGEN, F. Hoffm …
The Digital PCR and Real-Time PCR Market is witnessing substantial expansion driven by the growing demand for accurate, sensitive, and rapid diagnostic techniques. These technologies have become indispensable tools in molecular biology, clinical diagnostics, and research applications, particularly in areas such as oncology, infectious diseases, and genetic testing. The Digital PCR and Real-Time PCR Market size is projected to reach US$ 17.54 billion by 2031 from US$ 9.55 billion in…
Cystoscopy and Ureteroscopy Market 2026 | Stryker Corp, Rudra Surgicals, Telefle …
The global Cystoscopy and Ureteroscopy Market is witnessing significant expansion due to rising incidences of urological disorders and increasing adoption of minimally invasive diagnostic and therapeutic procedures. These endoscopic techniques are widely used for diagnosing and treating conditions such as kidney stones, bladder cancer, urinary tract infections, and ureteral strictures. The growing preference for precision-based urological interventions, coupled with advancements in high-definition imaging and flexible endoscope technologies, is significantly strengthening…
Anatomic Pathology Market is Expected to Register a CAGR of 7.3% during 2023-203 …
The anatomic pathology market is witnessing steady growth driven by rising incidences of cancer, increasing demand for accurate diagnostic techniques, and advancements in digital pathology. Anatomic pathology plays a crucial role in disease diagnosis by examining tissues and cells, making it indispensable in modern healthcare systems. The integration of artificial intelligence (AI), automation, and precision medicine is further enhancing diagnostic accuracy and efficiency across laboratories and hospitals worldwide.
Get Sample PDF:…
More Releases for Pharmacogenomics
Pharmacogenomics - Top Companies Regional and Data Analysis
Pharmacogenomics is a branch of science, which studies the role of gene over the activity of a drugs and hence helps the refreshers in predicting the response of novel as well as previously available therapies.
Get More Details with Sample PDF Copy @ https://www.theinsightpartners.com/sample/TIPRE00007564/?utm_source=OpenPR&utm_medium=10129
Major Companies operating in the Pharmacogenomics Market are:
• F. Hoffmann-la Roche Ltd
• Abbott
• Oxford Nanopore Technologies
• Thermo Fisher Scientific Inc.
• Illumina, Inc.
• QIAGEN
• Agilent Technologies, Inc.
• Myriad Genetics, Inc.
• Admera Health
Contact Us:
If you have any queries about…
Pharmacogenomics Market worth $5.8 billion by 2028
North America region is witnessing increasing investments and research activities in the field of drug discovery and development. The need for advanced therapies due to rising rate of cancer has contributed to growth of the pharmacogenomics market.
Pharmacogenomics Market [https://www.marketsandmarkets.com/Market-Reports/pharmacogenomics-market-142682251.html?utm_source=ABnewswire&utm_campaign=Paid&utm_content=Referral] in terms of revenue was estimated to be worth $3.5 billion in 2023 and is poised to reach $5.8 billion by 2028, growing at a CAGR of 10.6% from 2023 to…
Genetic Medicine: Unveiling the Power of Pharmacogenomics
Based on technology, the pharmacogenomics market is segmented into PCR, sequencing, microarray, gel electrophoresis, mass spectrometry, and others. The market for the PCR segment is subsegmented into real time PCR, standard PCR, and digital PCR. The PCR segment dominated the pharmacogenomics market in 2021 and is expected to register the highest CAGR during the forecast period.
Download Sample PDF Details at: https://www.theinsightpartners.com/sample/TIPRE00007564?utm_source=OpenPR&utm_medium=10776
The pharmacogenomics market is segmented on the basis of…
Complete PDF Guide On Pharmacogenomics [PDF]
According to our latest study on "Pharmacogenoics Market Forecast to 2028 - COVID-19 Impact and Global Analysis - by Technology, Application, and End User," the market is projected to reach US$ 14,107.80 million by 2028 from US$ 7,087.81 million in 2021; it is expected to grow at a CAGR of 10.3% from 2021 to 2028. The report highlights the key factors driving the market growth and prominent players with their…
Global Pharmacogenomics Market Size & Trends
According to a new market research report published by Global Market Estimates, the global pharmacogenomics market is projected to grow at a CAGR of 9.6% from 2023 to 2028.
The growth of the global pharmacogenomics market is driven by advancements in genomics and DNA sequencing technologies, the rising demand for personalized medicine, regulatory support from agencies like the FDA, cost-effectiveness through reduced adverse reactions, and a growing aging population with complex…
Global Pharmacogenomics Services Market Insights | 2022-2032
The Pharmacogenomics Services Market refers to the services provided by companies and laboratories that offer personalized medicine based on a patient's genetic makeup. Pharmacogenomics is the study of how an individual's genes affect their response to certain drugs, and the pharmacogenomics services market focuses on utilizing this knowledge to optimize drug therapy.
These services typically involve genetic testing to identify specific genetic variations that may impact a patient's response to certain…
